Method for producing a recombinant allotypespecific rabbit monoclonal antibody
A method for cloning a full length coding sequence for a light chain of a rabbit monoclonal antibody is provided. In some embodiments, this method may involve: fusing a B cell from a rabbit having a B4 allotype with a 240E cell or a derivative thereof to produce a hybridoma, wherein the B cell and the hybridoma produce a monoclonal antibody; making cDNA from the hybridoma; amplifying from the cDNA a full length coding sequence for the light chain of a monoclonal antibody produced by the hybridoma using: a forward primer that hybridizes to a site in SEQ ID NO: 10, and a reverse primer having a 3′ end of sequence CTARCAGTCX (SEQ ID NO: 11), wherein R is A or G and X is A, AC, ACC or ACCC; and cloning the amplified sequence into an expression vector to produce a first plasmid.
1. A method for producing a recombinant antibody having a b4 allotype, the method comprising the steps of:
a) providing a rabbit antibody-producing B-lymphocyte having a b4 allotype;
b) fusing the B-lymphocyte of step a) with a rabbit fusion partner having a b5 allotype to produce a hybridoma cell capable of producing an antibody;
c) making total cDNA from the hybridoma;
d) amplifying the heavy chain and the b4 light chain from the cDNA of step c) using:
(i) a light chain primer pair that comprises a forward primer having at the 3′ end the nucleotide sequence of SEQ ID NO: 1 and a reverse primer of 15-60 nucleotides in length having at the 3′ end the nucleotide sequence of SEQ ID NO: 12, 21 or 22, wherein the 3′ terminal nucleotide of the reverse primer is the 3′ terminal nucleotide of SEQ ID NO: 12, 21 or 22, and
(ii) a heavy chain primer pair that amplifies the coding sequence for the variable domain of the heavy chain;
e) cloning the amplified heavy chain and the light chain obtained in step d) into one or more plasmids downstream of an expression control sequence;
f) transfecting the plasmids into a mammalian host cell capable of expressing an antibody;
g) culturing the mammalian host cells under conditions suitable for antibody production;
h) isolating the antibodies produced in step g);
i) purifying the antibodies obtained in step h).
2. The method according to claim 1 , wherein the light chain reverse primer has the 3′ end of sequence CTARCAGTCACC (SEQ ID NO: 12), wherein the 3′ terminal nucleotide of the reverse primer is the 3′ terminal nucleotide of SEQ ID NO: 12.
3. The method of claim 1 , wherein the one or more plasmids comprises a promoter and terminator for expression of the light chain of a monoclonal antibody in a cell.
4. The method of claim 1 , wherein the light chain primer pair and the heavy chain primer pair of (d) (i) and (d) (ii), respectively, further comprise sequences that, in double stranded form, are cleavable by a restriction enzyme.
5. The method of claim 1 , wherein said fusion partner is 240E1-1-2, as deposited at the ATCC as accession number HB-11870.
6. The method according to claim 1 wherein the heavy chain primer pair comprises a forward primer having at the 3′ end the nucleotide sequence of SEQ ID No: 3 and a reverse primer having at the 3′ end the nucleotide sequence of SEQ ID No: 4.
7. The method according to claim 1 wherein the rabbit fusion partner having a b5 allotype is selected from 240E, 240E-1, 240E-1-1-2, 240E-W and 240E-W2.
8. A composition comprising:
a) cDNA from a rabbit hybridoma, wherein the cDNA comprises:
i. cDNA molecules encoding the variable domain of a rabbit immunoglobulin light chain that has a b4 allotype,
ii. cDNA molecules encoding the variable domain of a rabbit immunoglobulin light chain that has a b5 allotype;
iii. cDNA molecules encoding the variable domain of a rabbit immunoglobulin heavy chain; and
b) a PCR reagent comprising (i) a light chain primer pair that comprises a forward primer having at the 3′ end the nucleotide sequence of SEQ ID NO: 1 and a reverse primer of 15-60 nucleotides in length having at the 3′ end the nucleotide sequence of SEQ ID NO: 12, 21 or 22, wherein the 3′ terminal nucleotide of the reverse primer is the 3′ terminal nucleotide of SEQ ID NO: 12, 21 or 22; and (ii) a heavy chain primer pair that amplifies the coding sequence for the immunoglobulin heavy chain variable domain.
9. The composition of claim 8 , wherein the reverse primer of (b) (i) has the 3′ end of sequence CTARCAGTCACC (SEQ ID NO:12), wherein the 3′ terminal nucleotide of the reverse primer is the 3′ terminal nucleotide of SEQ ID NO: 12.
10. The composition of claim 8 , wherein the light chain primer pair and the heavy chain primer pair comprise sequences that, in double stranded form, are cleavable by a restriction enzyme.
11. The composition according to claim 8 wherein the heavy chain primer pair comprises a forward primer having at the 3′ end the nucleotide sequence of SEQ ID No: 3 and a reverse primer having at the 3′ end the nucleotide sequence of SEQ ID No: 4.